BidaskClub Downgrades Mast Therapeutics (SVRA) to Buy

BidaskClub downgraded shares of Mast Therapeutics (NASDAQ:SVRA) from a strong-buy rating to a buy rating in a research report released on Tuesday morning.

SVRA has been the topic of several other research reports. Zacks Investment Research downgraded shares of Mast Therapeutics from a buy rating to a hold rating in a research note on Friday, September 15th. Ladenburg Thalmann Financial Services began coverage on shares of Mast Therapeutics in a research note on Wednesday, January 3rd. They issued a buy rating and a $35.00 target price on the stock. Roth Capital reiterated a buy rating and issued a $40.00 target price on shares of Mast Therapeutics in a research note on Wednesday, September 27th. Jefferies Group began coverage on shares of Mast Therapeutics in a research note on Friday, September 22nd. They issued a buy rating and a $20.00 target price on the stock. Finally, ValuEngine downgraded shares of Mast Therapeutics from a sell rating to a strong sell rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $23.58.

Shares of Mast Therapeutics (SVRA) traded down $0.47 during midday trading on Tuesday, hitting $13.33. 154,926 shares of the stock traded hands, compared to its average volume of 166,200. The company has a market capitalization of $406.57, a P/E ratio of -3.97 and a beta of 0.18. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $17.19. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20.

In other news, Director Yuri Pikover bought 50,000 shares of the company’s stock in a transaction dated Friday, October 27th. The shares were purchased at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the purchase, the director now owns 150,000 shares in the company, valued at approximately $1,177,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 6.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades Mast Therapeutics (SVRA) to Buy” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/10/bidaskclub-downgrades-mast-therapeutics-svra-to-buy.html.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Analyst Recommendations for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit